

ABSTRACT OF THE DISCLOSURE

Compositions and methods for systemically minimizing the inflammatory effects of TNF- α are disclosed. The compositions include particles of bioactive glass with a particle size less than about 20 μm , alone or in combination with anti-inflammatory agents and other therapeutic agents. The compositions can include an appropriate carrier for oral, intramuscular, intraperitoneal or intravenous administration. When administered to a patient, the particles bring about elevated levels of IL-6 and do not cause elevated levels of TNF- α .

028870-178-04600